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Excessive activation of the hypothalamicepituitaryeadrenal (HPA) axis has been associated with
numerous diseases, including depression, and the tricyclic antidepressant imipramine has been shown
to suppress activity of the HPA axis. Central hypothalamic control of the HPA axis is complex and
involves a number of neuropeptides released from multiple hypothalamic subnuclei. The present study
was therefore designed to determine the effects of imipramine administration on the mouse hypo-
thalamus using a peptidomics approach. Among the factors found to be downregulated after acute
(one day) or chronic (21 days) imipramine administration were peptides derived from secretogranin
1 (chromogranin B) as well as peptides derived from cerebellin precursors. In contrast, peptides SRIF-14
and SRIF-28 (1e11) derived from somatostatin (SRIF, somatotropin release inhibiting factor) were
signiﬁcantly upregulated by imipramine in the hypothalamus. Because diminished SRIF levels have long
been known to occur in depression, a second part of the study investigated the roles of individual SRIF
receptors in mediating potential antidepressant effects. SRA880, an antagonist of the somatostatin-1
autoreceptor (sst1) which positively modulates release of endogenous SRIF, was found to synergize with
imipramine in causing antidepressant-like effects in the tail suspension test. Furthermore, chronic
co-administration of SRA880 and imipramine synergistically increased BDNF mRNA expression in the
cerebral cortex. Application of SRIF or L054264, an sst2 receptor agonist, but not L803807, an sst4
receptor agonist, increased phosphorylation of CaMKII and GluR1 in cerebrocortical slices. Our present
experiments thus provide evidence for antidepressant-induced upregulation of SRIF in the brain, and
strengthen the notion that augmented SRIF expression and signaling may counter depressive-like
symptoms.
This article is part of a Special Issue entitled ‘Anxiety and Depression’.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The hypothalamicepituitaryeadrenal (HPA) axis participates in
stress responses and is crucial to the maintenance of homeostasis
(Ulrich-Lai and Herman, 2009). Upon activation of the HPA axis,
a hormonal cascade is initiated in the brain, whereby hypothalamic
corticotropin-releasing hormone (CRH) induces secretion of adre-
nocorticotropic hormone (ACTH) from the anterior pituitary gland.ndrén), per.svenningsson@ki.
Y-NC-ND license.ACTH in turn induces secretion of glucocorticoids (cortisol in
humans, corticosterone in rodents) from the cortex of the adrenal
glands, the physiological effects of which are extremely diverse.
Thus, dysregulation of the HPA axis is associated with a plethora of
diseases, and HPA hyperactivation has been convincingly impli-
cated in depression (Chrousos, 2009). Chronic treatment with the
tricyclic antidepressant imipramine suppresses hyperactivity of the
HPA axis, as indicated by diminished secretion of ACTH and
glucocorticoids in humans and rats (Brady et al., 1991; Butterweck
et al., 2001; Frost et al., 2003; Michelson et al., 1997; Shimoda et al.,
1988), which potentially contributes to the antidepressant thera-
peutic effects of the drug (Michelson et al., 1997). Evidence avail-
able to date suggests that this is mediated centrally at the level
of the hypothalamus via inhibition of CRH-containing neurons
(Brady et al., 1991; Butterweck et al., 2001; Michelson et al., 1997).
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neuropeptides produced in multiple hypothalamic nuclei (Herman
et al., 2003). The present studywas therefore aimed at investigating
the effects of imipramine administration on the mouse hypothal-
amus using a peptidomics approach. Our goal was to identify
and quantify hypothalamic neuropeptides after acute (one day)
and chronic (21 days) imipramine administration, a strategy that
enables discovery of potentially novel mediators of antidepressant
mechanisms. The experiments were designed to include acute and
chronic time frames in order to address the delayed therapeutic
onset of antidepressant treatment known to occur in human
patients.
2. Materials and methods
2.1. Animals
Adultmale C57BL/6 (Charles River, Cologne, Germany) and FVB (own breeding at
Karolinska Institute of mice originating from a colony at Rockefeller University, New
York, USA) mice (25e30 g) were housed in a temperature- and humidity-controlled
facility under a 12 h light/dark cycle (lights on at 8:00 AM) in the Department of
Pharmacology at Karolinska Institute, Stockholm, Sweden. Standard rodent chow
and tap water were provided ad libitum. All procedures were performed according
to national (JO 887-848) and European (86/609/EEC) legislation governing animal
experimentation and were approved by a local ethics committee (N211/03). We
made every effort tominimize the number of animals used for the study and to avoid
any unnecessary distress.
2.2. Drugs
Imipramine hydrochloride was obtained from SigmaeAldrich (St. Louis, MO).
SRIF-14, L054264 and L803807 were obtained from Tocris Bioscience (Bristol, UK).
The somatostatin-1 receptor (sst1) antagonist SRA880 ([3R,4aR,10aR]-1,2,3,4,4a,
5,10,10a-Octahydro-6-methoxy-1-methyl-benz[g]quinoline-3-carboxylic-acid-4-(4-
nitro-phenyl)-piperazine-amide, hydrogen malonate) was from the Novartis Insti-
tutes for BioMedical Research (Hoyer et al., 2004). Drugs were freshly diluted in 0.9%
saline on the day of injection.
2.3. Experimental procedures in vivo
2.3.1. Acute and chronic administration of imipramine
In the experiment for subsequent neuropeptidomics analysis, three groups of
C57BL/6 mice received intraperitoneal (i.p.) injections of saline or imipramine
(10mg/kg) once per dayover the course of threeweeks. Twoof these groups received
saline daily for 20 days and one injection of saline (group “saline”) or imipramine
(group “acute imipramine”) on day 21. The third group received imipramine daily for
a total of 21 days (group “chronic imipramine”). To decrease enzymatic protease
activitieswhichwould degrade normal proteins into peptide fragments and interfere
with neuropeptide identiﬁcations and quantiﬁcations, these animals were sacriﬁced
by focused microwave irradiation and brains were quickly removed from the skull.
Samples of hypothalamus were rapidly dissected from the base of the brain using
a forceps and stored at 80 C until processing for mass spectrometry.
In another experiment, C57BL/6 animals received 21 days of treatment with
either saline or imipramine (10 mg/kg) and were killed by rapid decapitation. Brains
were dissected and frozen at80 C until analysis using in situ hybridization toward
Sst mRNA (encoding SRIF) or precursors of secretogranins and cerebellins.
2.3.2. Acute and chronic co-administration of the sst1 antagonist
SRA880 and imipramine
To address the effects of the interaction of the sst1 antagonist SRA880 and
imipramine on behavioral and neurochemical measures, FVB mice were used. In an
acute experiment, FVB mice received a single i.p. injection of saline, imipramine
(10 mg/kg), SRA880 (3 mg/kg) or imipramine together with SRA880. In a chronic
experiment, mice were treated once per day for 21 days with saline, imipramine
(10 mg/kg), SRA880 (3 mg/kg) or imipramine together with SRA880. Mice were
either used for behavioral studies, in situ hybridization or brain slice experiments.
For in situ hybridization, mice were killed by decapitation, brains were dissected and
frozen at 80 C. For brain slice experiments, mice were killed by decapitation,
brains were dissected and cortical slices made with a vibratome and incubated in
oxygenated artiﬁcial cerebrospinal ﬂuid (CSF) (see Section 2.9).
2.4. Sample preparation for mass spectrometry
Hypothalamic samples from the three different groups of mice (saline, n ¼ 5;
acute imipramine, n ¼ 6; chronic imipramine, n ¼ 6) were extracted and sonicated
(Vibra cell 750, Sonics & Materials Inc., Newton, CT, USA) in warm sample buffer(0.25% acetic acid/H2O, 0.2 mg tissue/ml) and then further denatured in a heating
block for 1 min. Cell debris were spun down for 45 min at 21,000  g. The super-
natant was transferred to a microﬁlter device with a cut-off limit of 10 kDa
(Microcon YM-10, Millipore, Bedford, MA, USA) and centrifuged for 45 min at
14,000  g. The peptide containing fraction was stored at 80 C until analysis.
2.5. Mass spectrometry differential display analysis
The peptide samples were randomized and analyzed on reversed phase nl/min-
ﬂow liquid chromatography (nano-LC; Ettan MDLC, GE Healthcare, Uppsala,
Sweden) electrospray ionization (ESI) quadrupole time-of-ﬂight mass spectrometry
(Q-Tof MS; Q-Tof2, Waters, Manchester, UK). Brieﬂy, 5 ml of each sample were
desalted on a trap column (1.0 mm i.d.  5 mm, packed with C18 PepMap100, 5 mm,
100 Å, LC Packings, Amsterdam, the Netherlands) and separated on a nano column
(75 mm i.d.  15 cm, packed with C18 PepMap100, 3 mm, 100 Å, LC Packings) during
a 40min gradient from 3% to 60% Buffer B (Buffer A: 0.25% acetic acid inwater, Buffer
B: 84% ACN, 0.25% acetic acid in water) at an approximate ﬂow of 170 nl/min.
Mass spectra were collected in the mass-to-charge ratio (m/z) range of
300e1000 with a mass resolution of 6800 atm/z 544.99 Da (z¼ 3). The rawMS data
were imported into DeCyder MS2.0 (GE Healthcare, Uppsala, Sweden) and aligned
and processed using the import and batch module. Peptide masses were automat-
ically detected using parameters such as elution time (0.8 min), typical peak reso-
lution (5000), accepted charge states (between 1 and 10), and background
subtracted quantiﬁcation. Manual veriﬁcation of the peptides was performed and
some peptides were removed or added manually in the PepDetect module. All the
ﬁles were then aligned and matched in the PepMatch module allowing for elution
time to differ up to 1 min and total mass to differ by 0.2 Da.
The peptide intensity maps were normalized using the DeCyderMS embedded
function of total intensity distribution normalization (Kaplan et al., 2007). A ﬁltering
criterionwhich only included peptides present in at least four samples in each group
was applied to the dataset. Differences between group means for the extracted
peptide data were analyzed by one-way analysis of variance (ANOVA) (GraphPad,
GraphPad Software Inc, San Diego, USA) followed by NewmaneKeuls test (pairwise
comparisons of groups), with signiﬁcance set to p < 0.05.
2.6. Mass spectrometry identiﬁcation of peptides
Peptide identiﬁcation was performed using either nano-LC ESI linear trap
quadrupole (LTQ) tandem MS (MS/MS) or nano-LC ESI LTQ Fourier Transform Ion
Cyclotron Resonance (FTICR) MS/MS (Thermo Electron, San Jose, CA, USA). The LC
conﬁguration was as described above. Data were collected on the LTQ using
a method containing three scan events, repeatedly. First a MS scan in the m/z range
300e2000, followed by a zoom scan of the most intense ion and MS/MS scan of the
same ion. A chosen peak was allowed to be selected twice before it was put on an
exclusion list for 150 s. The FTICR method consisted of ﬁve scanning events per-
formed repeatedly. First a MS scan betweenm/z 200 and 1500 followed by electron-
capture dissociation and collision-induced dissociation of the most intense and the
secondmost intense ion. A chosen ion peakwas then put on an exclusion list for 60 s.
The tandem MS data were converted into dta ﬁles using Xcalibur (version 2.0
SR2) and the dta ﬁles were then combined into mgf ﬁles using an in-house devel-
oped script. Tandemmass spectrawere assigned sequences by searching against two
targeted sequence collections, namely SwePep precursors and SwePep peptides
(Falth et al., 2007), using Mascot. These targeted sequence collections have been
developed using the SwePep database and provide fast, speciﬁc, and sensitive
identiﬁcation of endogenous peptides (Falth et al., 2007).
The SwePep precursor and the SwePep peptide sequence collections were
searched using unspeciﬁc cleavage and a peptide mass tolerance of 1.5 Da and
a fragment mass tolerance of 0.7 Da. The dataset was searched both with and
without a number of possible posttranslational modiﬁcations (N-terminal acetyla-
tion, N-terminal pyroglutamic acid of glutamine and glutamic acid, C-terminal
amidation, deamidation of asparagine and glutamine, phosphorylation, and oxida-
tion). Peptides identiﬁed with a score above the signiﬁcance cut-off (p < 0.05)
obtained from Mascot were collected. The false-positive rate was estimated by
searching the reversed sequence collections, calculating the number of hits over
a threshold, and dividing this number by the number of matches from the targeted
sequence collection search. If the false-positive rate was over 1% the threshold was
adjusted for that sequence collection.
For identiﬁcation of peptide sequences not present in the targeted sequence
collections the tandem MS data was also searched against UniProt (48.8) (Mus
musculus, unspeciﬁc cleavage). Additional endogenous peptides were identiﬁed by
mass matching of FTICR MS data to theoretical masses of endogenous peptides
present in SwePep. The quality of the samples was established by these searches
validating the presence/absence of the post-mortem degradation marker Stathmin
(2e20) (Skold et al., 2007).
2.7. Behavioral tests
For the tail suspension test (TST), mice were individually suspended by the tail
from a horizontal bar (distance from ﬂoor was 35 cm) using adhesive tape (distance
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behaviors interspersed with temporally increasing bouts of immobility. A 6-min
test session was videotaped and subsequently scored by an observer unaware of
treatment group. The scored parameter was the number of seconds spent immobile.
The open ﬁeld test (OF) was used to assess locomotor activity, and mice previously
used in the TST were allowed at least one week of recovery before OF testing was
carried out. Four identical square open ﬁeld arenas (outside size: 650  650 
325 mm; inside size: 500  500  225 mm) were used. The arenas were equipped
with two rows of photocells, sensitive to infrared light, placed 20 mm and 50 mm
above the ﬂoor. Photocells were spaced 31 mm apart, and the last photocell in a row
was spaced 17.5 mm from the wall. The open ﬁeld was enclosed in a ventilated,
sound-attenuated box (Kungsbacka Mät och Reglerteknik AB, Fjärås, Sweden).
Photocell beam interruptions were automatically recorded and scored (activity
count) on a computer. In both the tail suspension and open ﬁeld paradigm, mice
were tested 15 min after injection. Differences between groupmeans were analyzed
by one-way analysis of variance (ANOVA) (GraphPad) followed by NewmaneKeuls
test (pairwise comparisons of groups).
2.8. In situ hybridization
Frozen mouse brains were cut with a cryotome (Leica Microsystems AB, Kista,
Sweden) at 12 mm thickness and mounted on poly-L-lysine coated slides. Brain
subregions were identiﬁed with a brain atlas (Paxinos and Franklin, 2001). In situ
hybridization with synthetic oligodeoxynucleotides (Cybergene AB, Stockholm,
Sweden) or complementary RNA probes was carried out as previously described
(Svenningsson et al., 1995, 2003). The following oligodeoxynucleotide probes were
used for secretogranin precursors (Scg1e3) and cerebellin precursors (Cbln1, 2, 4):
Scg1, 50-CTACCTCTCGGCTGTGTCCTCCTCCTTCTCCACTTC-30; Scg2, 50-ACTCTCTCTCC
GGTTTTCTTCATCTGGGAGCCCCAACTGCCC-30; Scg3, 50-CCAAGAGCCGGTCCAAAGG
AACCCCATTCTTTCTTGCTT-30; Cbln1, 50-AGTCAAACCAGTCACCACGAAGGTGAGTCTTT
CCTTCGCTAACAA-30; Cbln2, 50-CAATGCCCAGCTCCCTCCCAAGACCCCCAAGACCCTAG
GGAAAAGC-30; Cbln4, 50-AGGGGAAGATGATGATCCCTTGGAGTCTGTAGCTGGGTTCG
AGTCG-30 . Oligodeoxynucleotide probes were radiolabeled using terminal deoxy-
nucleotidyl transferase (GE Healthcare, Uppsala, Sweden) and 35S-dATP (Du Pont,
New England Nuclear, Stockholm, Sweden) to a speciﬁc activity of about to
107 cpm/pg. Sections were hybridized in a cocktail containing 50% deionized
formamide (Fluka, Buchs, Switzerland), 4 SSC, 1 Denhardt’s solution, 1% sarcosyl,
0.02 M sodium pyrophosphate (Na4P2O7; pH 7.0), 10% dextran sulfate, 0.5 mg/ml
yeast tRNA (Sigma, Stockholm, Sweden), 0.06 M dithiothreitol, 0.1 mg/ml sheared
salmon sperm DNA, and 106 cpm/ml of probe. After hybridization for 15 h at 42 C,
the sections were washed four times, for 15 min each, in 1 sodium chlorideeso-
dium citrate buffer (SSC) at 55 C. Sections were subsequently brieﬂy dipped in
water, dehydrated through 70%, 95% and 99.5% ethanol, and ﬁnally air-dried.
Sections were apposed to Kodak MR ﬁlm for 3e5 weeks and ﬁlms were manually
developed (Kodak D19, Uniﬁx). Autoradiograms were digitized using a scanner
(Epson Perfection 4870 PHOTO) and densitometric quantiﬁcation was carried out
using Scion Image for Windows (alfa 4.0.3.2, Scion Corporation). Differences
between group means were analyzed by one-way analysis of variance (ANOVA)
(GraphPad Prism) followed by NewmaneKeuls test. Analyses of BDNF and Sst
mRNAs expression were carried out using complementary RNA probes covering
coding regions of BDNF (500 bp; amino acids 1e166 of proBDNF) or Sst (213 bp;
amino acids 44e115 of proSRIF), respectively. The BDNF probe was a kind gift of Drs
Michael Saxe and Rene Hen, Columbia University, New York, USA. The probes were
labeled with 35S-UTP and used for riboprobe in situ hybridization.
2.9. Preparation and incubation of cortical brain slices
for phosphorylation experiments
Mouse brains were rapidly removed and placed in ice-cold, oxygenated (95%
O2 þ 5% CO2) artiﬁcial cerebrospinal ﬂuid (aCSF) containing (in mM): 126 NaCl, 2.5
KCl, 1.2 NaH2PO4, 1.3 MgCl2, 2.4 CaCl2, 10 glucose and 26 NaHCO3, pH 7.4. Coronal
slices (300 mm thick) were prepared using a Leica vibratome (Leica, Germany).
Cortices were dissected from the slices in ice-cold aCSF buffer. Each slice was placed
in a polypropylene incubation tube with 2 ml of fresh aCSF buffer. The slices were
preincubated at 30 C under constant oxygenation (95% O2/5% CO2) for 60 min with
a change of buffer after 30 min. The buffer was then replaced with fresh aCSF and
slices were treated with SRIF-14, L054264 or L803807 (1 mM; Tocris) for 5 min. After
drug treatment, the samples were frozen on dry ice and stored at 80 C until
assayed.
2.10. Immunoblotting
Frozen tissue samples were sonicated in 1% SDS, transferred to Eppendorf tubes
and boiled for additional 10min. Small aliquots of the homogenatewere retained for
protein determination by the BCA protein assay method (Pierce, Rockford, IL, USA)
using bovine serum albumin as a standard. Equal amounts of protein (20 mg) were
loaded onto 12% acrylamide gels, and the proteins were separated by SDSePAGE and
transferred to Immobilion-P transfer membranes (0.2 mm) (Millipore, Solna,
Sweden). The membranes were immunoblotted using P-Ser831-GluR1 (1:500dilution; originally 06-772 from Upstate, Hauppauge, USA; now AB5847 from Mil-
lipore), P-Ser845-GluR1 (1:500 dilution; originally 06-773 from Upstate; now
AB5849, Millipore), P-Thr286-CaMKII (1:500 dilution; originally AB3827 from
Chemicon; now Millipore 06-881) or antibodies which are not phosphorylation
state-speciﬁc to estimate total levels of GluR1 (1:1000 dilution; originally 06-310
from Upstate; nowMillipore AB1504) or CaMKII (1:4000 dilution; originally 05-532
from Upstate; now Millipore 07-1496). The antibody binding was revealed
by incubation with goat anti-mouse or anti-rabbit horseradish peroxidase-linked
IgG (1:6000e8000 dilution) and the ECL immunoblotting detection system
(GE Healthcare). For the immunoblottings with P-Ser831-GluR1 and P-Ser845-GluR1,
crossreactive bands of a slightly higher molecular weight were found. This has been
observed previously in other studies (Snyder et al., 2000), and only the lower
speciﬁc bands of the expected molecular weights were quantiﬁed.
2.11. Data analysis and statistics
Autoradiograms from the in situ hybridization andwestern blotting experiments
were digitized using a Dia-Scanner (Epson Perfection 4870 PHOTO). Optical density
values were measured using Scion Image for Windows (Beta 4.0.22000 Scion
Corporation). Datawere analyzed with Student’s t-test, one-way ANOVA or two-way
ANOVA followed by pairwise comparisons, as indicated.
3. Results
3.1. Detected and identiﬁed peptides
An average of 466  72 peptides was automatically detected in
each sample of the nano-LC MS proﬁles using DeCyderMS.
Following manual curation, the number of detected peptides was
reduced to 408 45. All proﬁles were matched using the PepMatch
module, yielding 201 peaks present in all samples. Filtering for
peaks present in at least four samples per treatment group yielded
273 peaks. The total intensity distribution normalization reduced
the median coefﬁcient of variance for the detected peaks present in
all proﬁles by 17%.
In total, 78 hypothalamic peptides were identiﬁed from 24
different precursors (Supplementary Table 1). Of these, 64 were
identiﬁed by tandemMS data and database searches. An additional
14 peptides were suggested by mass matching of FTICR MS data
against theoretical masses of endogenous peptides present in
SwePep. Several of the detected peptides are known to have
biological functions, such as Met-enkephalin, Leu-enkephalin,
substance P, melanotropin alpha, and Arg-CLIP, while others
represent previously uncharacterized species derived from known
neuropeptide precursors. Many display characteristic neuropeptide
cleavage sites and some carry posttranslational modiﬁcations that
may indicate biological activity. Examples of the latter include the
C-terminally amidated peptide AEEEAVWGDGSPEPSPRE derived
from the corticotropinelipotropin precursor, or the secretogranin
1-derived peptide QKIAEKFSQ, posttranslationally modiﬁed by
N-terminal pyroglutamic acid. The quality marker stathmin (2e20)
was not identiﬁed in the hypothalamic samples from our present
study, hence they were considered to be of good quality with
respect to post-mortem degradation (Skold et al., 2007).
3.2. Peptides differentially regulated by imipramine administration
Statistical analysis revealed fourteen peptides that were signif-
icantly regulated according to ANOVA (see Supplementary Table 1
for all details). Four of these derive from the secretogranin 1
precursor (Fig. 1, top panel; SEESQEREY: F2,14 ¼ 3.94, p < 0.05;
SFARAPQLD: F2,14 ¼ 6.02, p < 0.05; LLDEGHYPVRESPIDTA:
F2,14 ¼ 6.38, p < 0.05; LLDEGHYPV: F2,14 ¼ 6.60, p < 0.05) and were
downregulated (30e62%) following chronic administration of
imipramine compared to saline controls. There was a similar
tendency for downregulation in mice treated acutely with imipra-
mine, but this reached signiﬁcance only for the peptide SFAR-
APQLD. Six differentially regulated peptides in the present dataset
Fig. 1. Regulation of hypothalamic neuropeptides by imipramine administration to C57BL/6 mice. Peptide ion intensities are expressed as mean log2 intensities  SEM (n ¼ 5e6).
The sequences of peptides derived from secretogranin 1, cerebellins 1, 2 and 4, as well as somatostatin (SRIF) are given above the respective graphs. Differences between groups
were analyzed by one-way ANOVA followed by NewmaneKeuls test for pairwise comparisons (different from saline: *p < 0.05, **p < 0.01; different from chronic imipramine:
#p < 0.05; see Supplementary Table 1 for all statistical details).
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lower panels; GSAKVAFSAIRSTNH: F2,14 ¼ 11.67, p < 0.001;
SGSAKVAFSAIRSTN: F2,14 ¼ 8.72, p < 0.01; SGSAKVAFSAIRSTNH:
F2,14 ¼ 8.50, p < 0.01; SGSAKVAFSATRSTNH; F2,14 ¼ 4.54, p < 0.05;
AANSKVAFSAVRSTN: F2,14 ¼ 4.12, p < 0.05; SKVAFSAVRSTN:
F2,14 ¼ 7.68, p < 0.01). The peptides SGSAKVAFSAIRSTNH and
GSAKVAFSAIRSTNH are annotated in UniProtKB as cerebellin and
des-Ser1-cerebellin, respectively. The peptides from cerebellin 2
and cerebellin 4 identiﬁed here correspond to sequences homolo-
gous to cerebellin 1. The three cerebellin 1-derived peptides (Fig. 1,
middle panel) were downregulated following acute (35e46%) and
chronic (40e54%) imipramine administration. This pattern of
regulation was similar for the cerebellin 4-derived peptides. Thus,
SKVAFSAVRSTN was downregulated 27% (acute) and 21% (chronic),
while the longer form AANSKVAFSAVRSTNwas downregulated 30%
following acute imipramine administration (Fig. 1, lower panel).
The cerebellin 2-derived peptide SGSAKVAFSATRSTNH was also
downregulated 40% following acute imipramine, but its abundance
almost returned to control levels following chronic administration
(Fig. 1, middle panel).
Expression of two peptides derived from the somatostatin (SRIF)
precursor was also regulated by imipramine administration (Fig. 1,
lower panel; SANSNPAMAPR: F2,14 ¼ 4.20, p < 0.05; AGCKNFF
WKTFTSC: F2,14 ¼ 4.07, p < 0.05). Abundance of the peptide
SANSNPAMAPR [SRIF-28 (1e11)] was found to be increased 75% in
hypothalamus of mice chronically treated with imipramine.
Peptide AGCKNFFWKTFTSC (SRIF-14) displayed a similar pattern
with an upregulation of 150%. This peptide was however only
identiﬁed by mass matching (mass accuracy 0.5 ppm). It is anno-
tated to contain a disulﬁde bridge which might contribute to the
lack of identity veriﬁcation by MS/MS data.
GAGENLGGSAVDDPAPLT, corresponding to the C-terminal part of
PACAP-related peptide (PRP), was regulated in the hypothalamus
(F2,14 ¼ 3.77, p < 0.05) and found to be increased 70% by chronic
imipramine administration (Supplementary Table 1). Finally, a
phosphorylated fragment derived from the neuroendocrine protein
7B2 was regulated (SVPHFSEEEKEAE þ Phospho: F2,13 ¼ 9.35,
p < 0.01) and found to be decreased 30% following chronic imipra-
mine administration. The unphosphorylated form of this peptideFig. 2. Regulation of neuropeptide transcripts in the hypothalamus of C57BL/6 mice by im
densitometry and are expressed as percentages relative to corresponding saline-treated co
istration were compared to saline-treated controls and analyzed by unpaired t-test (*p < 0.0
and downregulated Cbln1 (t ¼ 3.74, df ¼ 6). Representative ISH autoradiograms from salinwas also identiﬁed in the hypothalamic samples, expression levels of
which were unaffected by treatment (Supplementary Table 1).
3.3. In situ hybridization analysis of neuropeptide gene
expression after imipramine administration
To assess whether altered neuropeptide expression after imip-
ramine administration is paralleled by changes in expression of the
corresponding transcripts, in situ hybridization experiments were
carried out. Neither acute nor chronic administration of imipramine
had signiﬁcant effects on the expression of secretogranin precursor
transcripts 1 and 3 (Fig. 2), suggesting that changes in abundance of
the respective peptides occur at the posttranscriptional level.
Conversely, while no regulation of secretogranin 2-derived peptides
was found (Supplementary Table 1), chronic imipramine adminis-
tration caused a signiﬁcant increase in secretogranin 2 mRNA
expression in the hypothalamus (Fig. 2; t ¼ 3.58, df ¼ 5, p < 0.05).
A recent report (Miura et al., 2006) provided a comprehensive
analysis of cerebellin mRNA expression in the mouse brain. In the
present study, we veriﬁed that transcripts encoding cerebellin 1, 2
and 4 are expressed in mouse hypothalamus. Chronic administra-
tion of imipramine caused a consistent downregulation not only of
cerebellin 1-derived peptides (Fig. 1) but also of cerebellin 1 mRNA
(Fig. 2; t ¼ 3.74, df ¼ 6, p < 0.01), suggesting that imipramine may
regulate cerebellin 1 expression via a mechanism involving gene
transcription. Such regulation may be speciﬁc to cerebellin 1, since
chronic imipramine administration reduced peptide abundance
(Fig.1) but did not change transcript expression (Fig. 2) of cerebellin
2 and 4.
Abundance of Sst, the transcript encoding SRIF, was not statis-
tically signiﬁcantly affected by chronic imipramine administration
(Fig. 2). Thus, upregulation of SRIF-derived peptides (Fig. 1) seems
to occur through a posttranscriptional mechanism.
3.4. Behavioral effects of co-administration of imipramine
and SRA880
Having found imipramine-induced upregulation of SRIF
peptides in the hypothalamus, we asked whether blockade of theipramine administration. Results from in situ hybridization (ISH) were quantiﬁed by
ntrols (mean  SEM; n ¼ 3e5 mice per group). Effects of chronic imipramine admin-
5, **p < 0.01). Imipramine signiﬁcantly increased expression of Scg2 (t ¼ 3.58, df ¼ 5)
e-treated mice are shown above the corresponding graphs.
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would potentiate antidepressant-like behavior elicited by imipra-
mine in the tail suspension test (TST). In an experiment with
C57BL/6 mice, acute administration of imipramine strongly
reduced immobility time by 45% (data not shown). Administration
of SRA880 had no effect on its own and did not alter the afore-
mentioned response to imipramine. As has been reported earlier
(Mayorga and Lucki, 2001), several of the C57BL/6 mice (12%; data
not shown) climbed up their own tail during the TST. The profound
reduction of immobility time after acute imipramine administra-
tion (potential ceiling effect) and the tail climbing phenomenon
seen in C57BL/6 mice (potential exclusion of numerous subjects
from analysis) prompted us to use the FVB strain for this part of the
study instead. Mice from this strain have not been reported to climb
their tail, thus making them better suited for the TST procedure.
Furthermore, their response to imipramine is moderate, leading to
reductions of immobility time around 20% (Liu and Gershenfeld,
2003). In FVB mice, none of the acute treatments during our
study affected immobility time in the TST (Fig. 3), whereas results
differed between treatment groups in the chronic experiment
according to one-way ANOVA (F3,33 ¼ 5.55, p < 0.01). Chronic
administration of imipramine alone reduced immobility almost
20%, although this did not reach statistical signiﬁcance. Strikingly,
SRA880 potentiated this effect of imipramine during chronic co-
administration, leading to a signiﬁcant 40% decrease in immo-
bility time compared to saline-treated mice (NewmaneKeuls test
for pairwise comparisons, p < 0.01). Animals chronically treated
with SRA880 alone were indistinguishable from saline controls
(Fig. 3). Antidepressant-like effects of combined administration of
imipramine and SRA880 were not due to stimulation of locomotor
activity, as there were no signiﬁcant differences between any of the
four chronic treatment groups in the open ﬁeld test (Fig. 3). No
changes in thigmotaxis (i.e. activity in the periphery of the open
ﬁeld divided by the total activity) were found between groups,
neither after acute (saline 0.77  0.08; imipramine 0.84  0.10;
SRA880 0.73 0.11; imipramineþ SRA880 0.76 0.08) nor chronic
(saline 0.71  0.08; SRA880 0.57  0.06; imipramine 0.51  0.07;
imipramine þ SRA880 0.61  0.10 ) treatments.Fig. 3. Chronic co-administration of imipramine and the sst1 receptor antagonist SRA880
sessions (6 min) were videotaped and manually scored by a blinded observer. Results are ex
ﬁeld testing (15 min) was carried out using an automated systemmeasuring photocell beam
mean  SEM (n ¼ 7e10 animals per group). Differences between group means were an
(signiﬁcant differences between tail suspension results in the chronic experiment; F3,33 ¼ 5.5
saline: **p < 0.01; different from chronic imipramine: #p < 0.05; different from chronic
98.6  7.3 s in the acute and chronic experiments, respectively. Activity counts of saline-tr3.5. Effects of co-administration of imipramine and SRA880
on gene expression in the brain
The results from our peptidomic and behavioral analyses sug-
gested that imipramine-induced upregulation of SRIF and SRA880-
mediated disinhibition of SRIF signaling could synergize in causing
antidepressant-like effects. To test whether such synergy also
operates at the level of gene expression, we carried out in situ
hybridization for BDNF and Sst (encoding SRIF) mRNA in the brain.
BDNF is an activity-dependent gene which is upregulated by
various chronic antidepressant regimens, and two-way ANOVA
revealed a signiﬁcant main effect of time in our experiments
(F1,42 ¼ 12.93, p < 0.001). Post-hoc comparisons revealed no
signiﬁcant effects of imipramine or SRA880 alone on BDNF.
However, imipramine and SRA880 synergized upon chronic co-
administration and caused increased BDNF mRNA expression in
the cerebral cortex (Table 1 and Fig. 4; different from chronic saline,
p < 0.05). Effects of treatments did not reach signiﬁcance in the
other brain regions analyzed in the present experiments, and no
signiﬁcant changes in expression of Sst mRNA were found.
3.6. Effects of SRIF and selective sst2 or 4 receptor agonists on the
phosphorylation states of CaMKII and GluR1 in cortical brain slices
To further explore the mechanisms by which SRIF may regulate
activity-dependent processes in cerebral cortex, we studied the
effects of SRIF-14 on the phosphorylation states of CaMKII and
GluR1 in cortical brain slices from chronically saline- or
imipramine-treated mice (Fig. 5). It was found that SRIF-14 (1 mM)
increased P-Thr286-CaMKII both in saline and imipramine-treated
mice (saline-treated: t ¼ 2.45, df ¼ 10, p < 0.05; imipramine-
treated: t ¼ 2.51, df ¼ 10, p < 0.05). SRIF-14 also increased
P-Ser845-GluR1 (t ¼ 2.84, df ¼ 10, p < 0.05), but not P-Ser831-GluR1
(data not shown), in saline-treated mice. Similarly, L054264 (1 mM),
an sst2 agonist, increased P-Thr286-CaMKII in imipramine-treated
mice (t ¼ 2.62, df ¼ 10, p < 0.05) as well as P-Ser845-GluR1
(t ¼ 3.01, df ¼ 10, p < 0.05), but not P-Ser831-GluR1 (data not
shown), in saline-treated mice. In contrast, the sst4 agonist,produces synergistic antidepressant-like behavior in FVB mice. Tail suspension test
pressed as seconds of immobility time (mean  SEM; n ¼ 7e10 mice per group). Open
interruptions (activity counts) as an index of locomotion. Results are expressed as group
alyzed within the acute and chronic experiments, respectively, by one-way ANOVA
5, p < 0.01) followed by NewmaneKeuls test for pairwise comparisons (different from
SRA880: xp < 0.01). Immobility times of saline-treated mice were 116.5  14.3 and
eated mice in the open ﬁeld were 1260  225 per 15 min.
Table 1
Effects of co-administration of imipramine and the sst1 receptor antagonist SRA880 on gene expression of BDNF and Sst (SRIF) in the brain of FVB mice. Results from in situ
hybridization were quantiﬁed by densitometry and expressed as percentages relative to saline-treated controls, each within the acute and chronic experiment (mean  SEM;
n¼ 6e7mice per group). Differences were analyzed by two-way ANOVA followed by Bonferroni post-test. A signiﬁcant effect of time (F1,42¼12.93, p< 0.001) was found in the
case of BDNF in cortex, and post-hoc analyses showed a signiﬁcant difference (*p < 0.05) betweenmice chronically treated with saline and imipramineþ SRA880. DG, dentate
gyrus; CA1 - Cornu Ammonis 1; CA3 - Cornu Ammonis 3; Hypo, hypothalamus; imi, imipramine (10 mg/kg); sal, saline; SRA, SRA880 (3 mg/kg).
DG CA3 CA1 Cortex Hypo
Acute Chronic Acute Chronic Acute Chronic Acute Chronic Acute Chronic
BDNF
sal 100  12.5 100  16.1 100  8.3 100  11.3 100  8.8 100  12.5 100  13.9 100  13.1 100  26.3 100  41.8
imi 69.6  7.1 98.4  15.2 82.4  6.4 116.4  11.1 67.9  8 127.6  18.2 75.2  10.6 131.8  18.3 108.1  24.1 195.1  41.2
SRA 94.8  11.8 95.3  10.3 101.8  12 90.2  7.4 81.9  11.7 98.6  11.3 91.5  16.4 119  17.3 143.9  60.1 109.5  24.1
imi þ SRA 81.1  10.4 128.9  18.3 82.3  11 120.6  9.5 64.7  11 134.9  12.4 84.1  15.2 152.1  12.4* 121.3  34.7 185.5  39.6
Sst (SRIF)
sal 100  16.9 100  10.8 100  17.6 100  14.4 100  7.3 100  11.4 100  9.9 100  6.8 100  12.9 100  16
imi 115  15.9 86.4  7.2 126.1  17.4 108.9  14.6 103.5  10.8 124.8  11.4 121.3  12.3 86.9  8.5 71.2  6.2 121.7  20.9
SRA 95.2  6.7 113.7  14.3 102  22.6 111.2  18.5 103.6  9.2 127.4  14.5 107  7.9 94.8  11.4 94.3  17.2 120.6  12.8
imi þ SRA 126.1  14.8 89.8  9.2 123.9  17.9 88.6  9.5 138.7  21.7 115.1  10.2 130.1  11 81.6  6 117.6  11.5 101  28.8
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states of CaMKII and GluR1 in the cortical slices (Fig. 5). There were
no changes on P-Ser831-GluR1 or on the total levels of CaMKII or
GluR1 in any of the treatment groups.
4. Discussion
By performing a “neuropeptidomics” study of the mouse
hypothalamus after imipramine administration, the present
study was aimed at identifying potentially novel mediators of
antidepressant-induced signaling in the brain. More detailed
analysis of SRIF, a candidate arising from this discovery approach,
contributes evidence to the growing body of literature implicating
neuropeptides in the control of stress, anxiety and depression.
4.1. Neuropeptidomic analysis of mouse hypothalamus
after imipramine administration
Efﬁcient sample preparation (Skold et al., 2007; Svensson et al.,
2003) together with nano-LC MS proﬁling allows for the simulta-
neous detection and identiﬁcation of a great number of peptides.
Mass spectrometric analysis provides the ability to differentiate
between unique peptides derived from the same precursor, setting
it apart from conventional techniques, such as Western blotting or
radioimmunoassay, which are limited in multiplexing capability
and differentiation of individual peptide species. Furthermore, in
conventional assays, the peptides investigated have to be known
a priori, whereas our method enables unbiased discovery of novel
species. In the present study, we were able to identify and quantify
78 peptides from mouse hypothalamic tissue samples. The use of
a sample preparation protocol that includes a quality control for
post-mortem degradation (Skold et al., 2007) and targeted neuro-
peptide sequence collections (Falth et al., 2007) increases theFig. 4. Expression of BDNF mRNA in the forebrain after chronic administration of imipramin
situ hybridization experiments are shown for cortex and hippocampus (see Table 1 for numquality and peptide identiﬁcation efﬁciency of the ﬁnal analysis.
The majority of the peptides identiﬁed here were derived from
precursors known to yield bioactive fragments, and many were
cleaved from sites speciﬁc to prohormone convertases (Falth et al.,
2007). These facts and additional characteristics, such as the pres-
ence of posttranslational modiﬁcations, speak in favor of such
peptides being biologically active, providing a starting point for
more detailed investigation.
It should be pointed out that several important hypothalamic
neuropeptides were not detected using the method described in
the present report, including corticotropin-releasing hormone
(CRH), pituitary adenylate cyclase-activating polypeptide (PACAP),
vasoactive intestinal peptide (VIP) and galanin. All these peptides
are relatively large molecular weight peptides (around 5000 Da)
and might not be captured efﬁciently into the aqueous extraction
solution used in our procedure. Furthermore, it is known that some
peptides, such as CRH, are prone to adsorb to surfaces or bind to
larger proteins (Behan et al., 1995; Kertscher et al., 1998), hence
limiting their passage through the 10 kDa cut-off ﬁlter. Vasopressin
was identiﬁed but found not to be changed after imipramine
administration (Supplementary Table 1). Full-length somatostatin
(SRIF-28), of which SRIF-14 is a fragment, was also not detected in
our assay. Nonetheless, the successful identiﬁcation of several novel
candidates, and the functional validation of SRIF-14 as a potential
mediator of imipramine-induced antidepressant-like effects (see
below), clearly shows the usefulness of our peptidomics approach.
4.2. Potential roles of differentially regulated peptides in mediating
imipramine-induced effects
Numerous psychiatric conditions, including depression, have
been associated with excessive activity of the hypothalamice
pituitaryeadrenal (HPA) axis, the cardinal feature of which ise, SRA880 or a combination of both agents to FVB mice. Representative images from in
erical results from all brain regions).
Fig. 5. Effects of SRIF, L054264 (sst2 agonist) and L803807 (sst4 agonist) on the phos-
phorylation states of CaMKII and GluR1 in cerebrocortical slices from chronically saline-
or imipramine-treated FVB mice. (A) SRIF (1 mM) increased P-Thr286-CaMKII both in
saline and imipramine-treated mice (saline-treated: t ¼ 2.45, df ¼ 10; imipramine-
treated: t ¼ 2.51, df ¼ 10), while P-Ser845-GluR1 was increased only in saline-treated
mice (t ¼ 2.84, df ¼ 10) and P-Ser831-GluR1 was unchanged (data not shown). (B)
L054264 (1 mM) increased P-Thr286-CaMKII in imipramine-treated mice (t ¼ 2.62,
df ¼ 10), as well as P-Ser845-GluR1 in saline-treated mice (t ¼ 3.01, df ¼ 10), without
affecting P-Ser831-GluR1 (data not shown). (C) The sst4 agonist L803807 (1 mM) had no
signiﬁcant effects on the phosphorylation states of CaMKII and GluR1. For the immu-
noblottings with P-Ser831-GluR1 and P-Ser845-GluR1, crossreactive bands of a slightly
higher molecular weight were found. Only the lower speciﬁc bands of the expected
molecular weights were quantiﬁed. Results are expressed as group mean  SEM (n ¼ 6
slices per treatment group). Differences were analyzed by unpaired t-test (*p < 0.05).
A. Nilsson et al. / Neuropharmacology 62 (2012) 347e357354glucocorticoid hypersecretion (Chrousos, 2009). The tricyclic drug
imipramine is effective against depression and suppresses the HPA
axis (Brady et al., 1991; Butterweck et al., 2001; Frost et al., 2003;
Michelson et al., 1997; Shimoda et al., 1988), which has led to the
suggestion that HPA suppression is a component of imipramine-
induced therapeutic responses (Michelson et al., 1997). However,
the underlying mechanisms have yet to be elucidated, and addi-
tional pathways may exist. In the present study, we provide
evidence indicating that antidepressant responses in the brain
involve differential regulation of neuropeptides.
4.2.1. Downregulation of secretogranin 1 and cerebellin-derived
peptides in the hypothalamus
Secretogranin 1 (also called chromogranin B) belongs to the
granin family of secretory proteins. These acidic proteins are major
components of secretory vesicles and involved in the packaging
and release of neurotransmitters and hormones [see (Taupenot
et al., 2003) for review]. Several fragments of secretogranin 1
have been described, some of which are biologically active in
different tissues (Taupenot et al., 2003), but there is currently no
evidence for these fragments playing a role in hypothalamic func-
tion. Of the four secretogranin 1 fragments detected in the present
study, three have previously been found in hypothalamic tissue by
Dr. L. Fricker’s laboratory [see for example (Wardman et al., 2010)],
whereas the peptide SEESQEREY has been described by us (Nilsson
et al., 2009). The fact that all four fragments were found to be
downregulated after imipramine administration suggests a regula-
tory mechanism reducing overall expression of secretogranin 1,
which most likely does not proceed via regulation of gene
expression, given that Scg1 mRNA was unaffected by chronic
imipramine. Additional experiments will be necessary to deter-
mine the nature of the regulatory mechanism and its potential
consequences.
Peptidomic analysis of the mouse hypothalamus also revealed
several peptides from the cerebellin family to be downregulated in
response to imipramine treatment. Cerebellin (derived from the
cerebellin 1 precursor) was ﬁrst discovered in the cerebellum and
proposed to be a speciﬁc marker for this brain region (Slemmon
et al., 1984). It is now known that the genes encoding cerebellins
(Cbln1e4) are expressed in many regions of the mouse brain,
including the hypothalamus, with the exception of Cbln3 (Miura
et al., 2006). Depolarization-induced, calcium-dependent release
from hypothalamic slices indicated that cerebellin is a putative
neurotransmitter in the hypothalamus (Burnet et al., 1988), and
recent peptidomic data from the rat suprachiasmatic nucleus sug-
gested a role in circadian rhythms (Lee et al., 2010), but functional
evidence supporting these notions is still lacking. Nonetheless, we
found a signiﬁcant reduction in expression of cerebellin 1 peptide
and transcript in response to imipramine administration. Regarding
the identiﬁcation in our study of peptides derived from the cer-
ebellin 1 precursor, it is worth noting that full-length cerebellin (16
amino acids) as well as a shorter form (lacking the ﬁnal histidine)
were previously identiﬁed in peptidomic studies of mouse hypo-
thalamus (Che et al., 2007) and rat suprachiasmatic nucleus
(Lee et al., 2010).
4.2.2. Upregulation of SRIF in the hypothalamus e potential effects
on stress responses
Our present results show that imipramine signiﬁcantly induces
expression of somatostatin (SRIF) in the mouse hypothalamus. SRIF
has long been implicated in disorders of the central nervous system
(CNS), including depression, based on the ﬁnding that SRIF
concentrations in cerebrospinal ﬂuid (CSF) from depressed patients
are lower compared to control subjects [see (Bissette and Myers,
1992; Markou et al., 1998) for review]. Previous studies found no
imipramine
?
SRIF
antidepressant-like effects                 
(sst2, sst3)
sst1
SRA880 Pharmacological entry point      
(parallel approach)
Endogenous SRIF system with 
negative feedback element
Physiological outcome
Fig. 6. Proposed mechanism by which co-administration of imipramine and SRA880
elicits enhanced antidepressant-like effects. Imipramine-induced upregulation of
somatostatin (SRIF) in the brain is limited by sst1-mediated negative feedback.
Blockade of negative feedback via the sst1 antagonist SRA880 facilitates imipramine-
induced regulation of SRIF, thereby enhancing its antidepressant-like effects, which
are most likely mediated by sst2 and sst3 receptors. Black lines indicate blockade or
inhibitory action. Open arrows indicate stimulation. The question mark indicates that
the mechanism by which imipramine upregulates SRIF remains to be investigated.
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in rat brain (Kakigi et al., 1992) or human CSF (Lepola et al., 1989;
Rubinow et al., 1985), but species (mouse versus rat and human)
and assay (present approach versus radioimmunoassay) may
account for these differences.
Using our peptidomics approach, we detected four peptides
derived from the SRIF precursor whose expression was differen-
tially regulated inmouse hypothalamic tissue. Of these, SRIF-14 and
SRIF-28 (1e11) were upregulated after chronic imipramine
administration, whereas SRIF-28 (1e12) and its oxidized formwere
unchanged relative to saline-treated control mice. To our knowl-
edge, SRIF-28 (1e11) has only been described as a tryptic fragment
of SRIF-28 (Esch et al., 1980; Gluschankof et al., 1985). Whether it is
a degradation product of our assay procedure is not clear at present,
since the enzyme responsible for cleaving SRIF-28 into SRIF-14 and
-28 (1e12) in the CNS does not generate SRIF-28 (1e11)
(Gluschankof et al., 1985). On the other hand, a signiﬁcant body of
evidence exists regarding the distribution and function of SRIF-14
and SRIF-28 (1e12) in the CNS. Both peptides are released from
the hypothalamus and median eminence, with some data sug-
gesting that release is selective (Bakhit et al., 1984). In addition,
both peptides are secreted into hypophyseal portal blood in the rat
(Millar et al., 1983; Sheward et al., 1984). While there is ample and
solid evidence for effects of SRIF-14 in the CNS, no physiological
role for SRIF-28 (1e12) has been described yet. For example,
intracerebroventricular (i.c.v.) infusion of SRIF-14 increases hypo-
thalamic serotonin and dopamine concentrations, facilitates
avoidance learning and dose-dependently affects locomotor
behavior in rats, while SRIF-28 (1e12) is inactive (Vecsei and
Widerlov, 1990; Vecsei et al., 1990). Furthermore, neuronal
activity in hippocampus and brain stem is modulated by SRIF-14,
but unaffected by SRIF-28 (1e12) in vitro (Jacquin et al., 1988;
Watson and Pittman, 1988). Upregulation of SRIF-14 as observed
in our present study therefore represents upregulation of a physi-
ologically relevant peptide species.
In vivo, SRIF inhibits stress-induced ACTH secretion without
affecting its basal concentrations (Brown et al., 1984; Petraglia et al.,
1986). Since it does not affect ACTH secretion induced by admin-
istration of CRH (Brown et al., 1984; Stafford et al., 1989), it has been
hypothesized that the HPA-inhibitory effect of SRIF is mediated
centrally via inhibition of CRH release from the hypothalamus
(Brown et al., 1984). According to Brown et al., this effect is elicited
by SRIF-28 but not SRIF-14 (Brown et al., 1984). Of note, CRH-
induced ACTH secretion is signiﬁcantly diminished by the SRIF
analog and sst1/2/3/5 receptor agonist SOM230 (Silva et al., 2005).
The bulk of the literature thus supports the notion that SRIF
suppresses activity of the HPA axis in the brain speciﬁcally during
stress responses.
4.2.3. Disinhibition of SRIF signaling in the brain e antidepressant-
like effects
In line with its aforementioned inhibitory impact on the HPA
axis during stress, SRIF infused into the cerebral ventricles causes
antidepressant- and anxiolytic-like effects in rats (Engin et al.,
2008), most likely mediated by the sst2 and sst3 receptor
subtypes (Engin and Treit, 2009). Motivated by these recent reports
and our ﬁnding that SRIF-14 is upregulated inmouse hypothalamus
after imipramine administration, we investigated whether SRIF
signaling affects behavioral tests of depressive-like symptoms in
mice. For this purpose, we used an antagonist of the sst1 receptor
that has recently been shown to increase release of endogenous
SRIF-14 in the hippocampus (De Bundel et al., 2010) and nucleus
accumbens (Vasilaki et al., 2004). In other words, we selected
a pharmacological agent that e via inhibition of the inhibitory sst1
autoreceptor (Thermos et al., 2006) e enhances SRIF signaling inthe brain, speciﬁcally at those neurons that express and release SRIF
endogenously. Our results show that chronic administration of the
compound SRA880 (Hoyer et al., 2004) synergizes with chronic
imipramine in causing antidepressant-like behavior (reduced
immobility time) in the tail suspension test, without exerting
effects on its own. The tail suspension test is widely used as amodel
to assess antidepressant-related behavior (Cryan et al., 2005),
however, it should be recognized, that its use is best exploited
when used in battery style fashion with other depression models
such as learned helplessness, anhedonia models, social defeat and
novelty-induced hypophagia. It will be important, in future studies,
to study the interaction between SRA880 and imipramine in
additional antidepressant-related tests. Nonetheless, our data is in
overall agreement with results cited byWeckbecker et al. according
to which SRA880 affects behavioral indices of anxiety, depression
and bipolar disorder in mice (Weckbecker et al., 2003), although
indices of anxiety (e.g. thigmotaxis in the open ﬁeld test) were not
affected in our studies. Furthermore, our experiments show that
chronic co-administration of SRA880 and imipramine elicits
a signiﬁcant increase in BDNF mRNA expression in the cerebral
cortex. Given the activity-dependent regulation of BDNF and its role
in neuronal plasticity and depression (Duman and Monteggia,
2006), this ﬁnding presents an important lead for future experi-
ments aimed at further elucidating the molecular consequences of
combined treatment with imipramine plus SRA880. To start to
address this question, we performed experiments in cere-
brocortical brain slices from mice chronically treated with saline or
imipramine. Because SRA880 disinhibits SRIF release, wemimicked
the probable action of SRA880 by applying SRIF directly onto the
brain slices. It was found that SRIF increased the phosphorylation
states of CaMKII and GluR1, postsynaptic proteins known to regu-
late neuronal activity, both in slices from saline- and imipramine-
treated mice. There is limited data on the impact of SRIF on
neuronal activity in cortical circuitry in mice, but experiments from
hippocampus have implicated sst2 and sst4 receptors in the regu-
lation of excitatory neurotransmission (Moneta et al., 2002).
Stimulation of sst2 receptors has also been linked to activation of
CaMKII in cell lines (Liu and Wong, 2005). Both sst2 and sst4
receptors are expressed in cortex (Thoss et al., 1995) and we
therefore treated slices with agonists selective for these receptor
A. Nilsson et al. / Neuropharmacology 62 (2012) 347e357356subtypes. It was found that application of an sst2, but not sst4,
agonist had similar effects as SRIF on regulating the phosphoryla-
tion states of CaMKII and GluR1. Taken together with results from
the literature, our data thus support the notion that sst1 functions
as an inhibitory autoreceptor whose inhibition (through SRA880)
enables induced SRIF release to stimulate postsynaptic sst2 recep-
tors. Fig. 6 provides a schematic summary of the pathway proposed
on the basis of previous results and our present study. Recent data
indicate that the sst1 receptor itself may be upregulated in the
hippocampal CA1 region after treatment with desipramine, an
antidepressant drug and active metabolite of imipramine (Pallis
et al., 2009). In the present study, we found no change in Sst
mRNA (encoding SRIF) in the hippocampus, and more work is
needed to fully characterize the plasticity of the SRIF system in
response to antidepressants.
In conclusion, our present report provides an example of how
neuropeptidomics can be used as a powerful approach to discov-
ering mediators of antidepressant action in the brain. The most
prominent candidate emerging from our experiments is SRIF,
a peptide long implicated in psychiatric diseases, and its functional
validation in a rodent test of depressive-like behavior yields novel
clues as to how SRIF signaling may be employed to counter
depressive symptoms in humans.
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